期刊
CURRENT DIABETES REPORTS
卷 13, 期 3, 页码 307-318出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-013-0377-9
关键词
GLP-1; DPP-4; GLP-1 receptor agonists; DPP-4 inhibitors; Incretin; Type 2 diabetes; Weight loss; Hypoglycemia; Cardiovascular risk factors
资金
- NIH grant [DK083554]
Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据